Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation

SAN FRANCISCO and GENEVA, July 30, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and…Read More »

Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest

NEW YORK and MINNEAPOLIS, July 30, 2014 (GLOBE NEWSWIRE) — Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biot…Read More »

Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations

MINNEAPOLIS, SAN FRANCISCO and NEW YORK, July 28, 2014 (GLOBE NEWSWIRE) — Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQ…Read More »

Amarantus Appoints Donald D. Huffman to Board of Directors

Mr. Huffman to Chair Audit Committee SAN FRANCISCO and GENEVA, July 28, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and…Read More »

Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations

NEW YORK and SAN FRANCISCO, July 23, 2014 (GLOBE NEWSWIRE) — Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a bi…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
Phone: (408) 737-2734
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Aimee Boutcher, Director of Investor Relations
Phone: (408) 737-2734 x 101
ir@amarantus.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy